Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Regeneron Pharmaceuticals Receives Dupixent Approval in Japan

April 12, 2025
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has recently received approval for its drug Dupixent in Japan. Despite this positive news, the company's stock, symbol REGN on NasdaqGS, has dropped 10% over the last week. However, experts from Stocks Prognosis recommend considering the long-term potential of Regeneron Pharmaceuticals' stock movement before making any investment decisions. The company's innovative approach to drug development and its recent success in obtaining regulatory approvals make it a promising player in the pharmaceutical industry.

Find out how the REGENERON PHARMACEUTICALS, INC. rate is expected to change

Get Forecast for REGN

Investor opinions & comments:

Regeneron Pharmaceuticals' recent drop in stock price raises concerns. It's important to thoroughly evaluate the company's long-term potential before considering any investments
— from JaxonBarnes at 04-15-2025 17:42
This approval in Japan could significantly expand Regeneron Pharmaceuticals' market reach. It's worth considering their long-term potential before making any investment decisions
— from InvestorIshmael at 04-15-2025 03:45
Despite the recent drop in stock price, Regeneron Pharmaceuticals' long-term potential should not be overlooked. Their success in obtaining regulatory approvals shows promising growth prospects
— from DividendDiane at 04-15-2025 03:11
The recent stock drop despite the approval in Japan raises doubts about Regeneron Pharmaceuticals' future performance. Further analysis is needed before considering any investments
— from MoneyMark at 04-14-2025 23:42
Esta aprobación en Japón debería abrir nuevas oportunidades de mercado para Regeneron Pharmaceuticals. Es interesante considerar su potencial a largo plazo antes de tomar decisiones de inversión
— from SavvySusan at 04-14-2025 06:03
Regeneron Pharmaceuticals has been making notable progress in drug development and obtaining regulatory approvals. Their innovative approach to the pharmaceutical industry makes them a promising player
— from AdamWells at 04-13-2025 10:19
Despite the approval in Japan, Regeneron Pharmaceuticals' stock has experienced a significant drop. It would be wise to carefully assess the company's outlook before making any investment decisions
— from MoneyMiles at 04-13-2025 00:22
Regeneron Pharmaceuticals' approval for Dupixent in Japan is a significant milestone. Their innovative approach and recent success make them a promising investment in the pharmaceutical industry
— from RiskyRachel at 04-12-2025 16:22
Regeneron Pharmaceuticals' recent approval in Japan is a positive development for the company. It's worth looking into their long-term prospects
— from SofiaLong at 04-12-2025 12:05
If you want to leave a comment, then you need Login or Register





Other news for REGN

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast, Bringing 27.31% Profit  ~1 min.

On March 4, 2025, QuantWave, the automated forecasting platform, issued a short signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at $674.49....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits 29.73% Profit Target as Forecasted by QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) achieved a significant milestone as it hit the price target forecasted by QuantWave, providing investors with a profit of 29.73%....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 21.51% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave, resulting in a profitable outcome for investors....



Related news

REGNFebruary 3, 2025Regeneron Pharmaceuticals Inc. Receives Positive Analyst Recommendations  ~1 min.

Regeneron Pharmaceuticals Inc. (REGN) has recently received bullish recommendations from leading analysts, indicating a positive outlook for the company's future....

REGNJanuary 24, 2025Regeneron Pharmaceuticals, Inc. Announces Positive Results from Clinical Trial of its Breakthrough Drug  ~1 min.

Regeneron Pharmaceuticals, Inc., a leading biotechnology company, has recently announced positive results from a clinical trial of its groundbreaking drug....

REGNFebruary 13, 2025Analyst Cuts Regeneron Pharmaceuticals REGN Price Target After Sales Concerns and Investor Lawsuit Hagens Berman  ~2 min.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) faced a setback as an industry analyst recently cut the company's price target....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....

REGNFebruary 6, 2025Regeneron Pharmaceuticals Inc. faces legal action for Securities Law Violations - Seek advice from The Gross Law Firm  ~2 min.

Regeneron Pharmaceuticals Inc., a leading biotechnology company, is currently facing a lawsuit for alleged violations of securities laws....